The name CJC-1295 has been applied to more than one peptide molecule. The original scientific publications described an albumin-binding GHRH analogue. Subsequently, a shorter peptide was identified as CJC-1295. This article outlines the specifics of each of the CJC-1295 molecules that have been studied, and the data which was collected regarding each of them, including the frequently-cited half-life of the original long-acting molecule.
Key findings
- Albumin attachment was part of the original CJC-1295 design, not an incidental finding.
- The often-quoted half-life, 5.8 to 8.1 days, came from Teichman’s adult trials of the long-acting molecule.
- GH pulses persisted in a separate human study. The trough between them rose, though, so “unchanged secretion” would be the wrong description.
- Protein-bound CJC-1295 presented a different detection problem from free peptide in later analytical work.
The chemistry comes first
Note on terminology: GHRH refers to the releasing hormone. GH is the hormone whose release from the pituitary was measured in the studies discussed here. CJC-1295 belongs on the GHRH side of that sentence. It is not another name for GH.
This work precedes the synthesis of CJC-1295 and in 1992 Mayo and colleagues expressed the human GHRH receptor in kidney cells. These cells bound GHRH with high affinity and in a highly specific manner. Stimulation of these cells with GHRH increased cyclic AMP production. The human GHRH receptor is a 7 membrane spanning receptor and therefore is a member of the G protein-coupled receptor superfamily. In the rat, receptor mRNA was predominantly expressed in the anterior pituitary. The purpose of this work was to provide background regarding the parent ligand and receptor and it is not intended as part of the evaluation of CJC-1295.
Now for the chemical details of the CJC-1295 in Jetté’s 2005 study. This CJC-1295 was a tetrasubstituted GHRH(1-29) analogue with a modified lysine added at the C terminus. That lysine carried a maleimide-containing group. This group reacted with the free thiol at Cys34 on albumin, making a covalent bond. The phrase “Binds to albumin” must be remembered to mean covalently attached in this case.
However, attachment to albumin would be of little use if it rendered the ligand inactive. The conjugated analogs examined by Jetté et al. still elicited GH secretion from cultured rat anterior pituitary cells. Furthermore, in vitro studies revealed that the related albumin conjugates had greater stability against dipeptidylpeptidase-IV. In rats, the two-hour GH secretion area under the curve for CJC-1295 was fourfold that of the parent GHRH(1-29) fragment. That comparison is specific to the two-hour GH area under the curve. It does not establish a general fourfold difference in potency.
DAC is the abbreviation used for the albumin-binding feature, short for drug affinity complex. The DAC versus non-DAC comparison is described elsewhere in this library. There are separate entries for CJC-1295 DAC and CJC-1295 without DAC. For now, the point is simply not to mistake a shared label for an identical structure.
Read the measurements, not just the headline
The Teichman study (Teichman et al., 2006) is the one usually behind the “about a week” figure. It was a set of two randomized, double-blind, placebo-controlled trials in healthy adults aged 21 to 61 years, with observation periods of 28 and 49 days. Three end-points were measured: CJC-1295, growth hormone and insulin-like growth factor I (IGF-I).
Based on the abstract, GH had a mean increase of twofold to tenfold for 6 days or more after a single exposure of CJC-1295. The mean IGF-I rose 1.5-fold to 3-fold for 9 to 11 days after a single exposure of CJC-1295. Also, CJC-1295 had an estimated half-life of 5.8 to 8.1 days and showed evidence of accumulation with repeated exposure of the compound. Thus all of these data cannot be rounded up to about a week of the compound’s effects.
Don’t use IGF-I and GH numbers in a sample to try to reverse calculate the amount of peptide in that sample. The studies in this review were not performed to assess pharmacokinetics of a compound. The half-life figure is the one pharmacokinetic measurement of the compound here.
A second study by Ionescu and Frohman assessed the GH secretion profile of healthy men 20 to 40 years of age prior to and one week after exposure of CJC-1295. The studies were conducted with blood sampling every 20 minutes over a 12-hour overnight period. GH pulse frequency and magnitude did not change after CJC-1295 exposure. However, there were marked increases in mean GH levels (46%) and in IGF-I levels (45%) as well as in trough GH levels (7.5-fold).
“Pulsatility was preserved” is not quite complete as the lowest points between the peaks actually increased during exposure. Therefore, it would be misleading to state that the profile remained unchanged.
The evidence discussed here relating to pituitary RNA comes from Alba and colleagues (2006). In GHRH-knockout mice exposed to CJC-1295, total pituitary RNA and GH mRNA increased. Immunohistochemistry supported somatotroph proliferation. However, this is a study on mice. It cannot be assumed to be relevant to all pituitary tissue.
Body length, femur length and tibia length were also measured. Placebo-exposed GHRH-knockout mice and mice heterozygous for the GHRH-knockout allele served as comparison groups in the study.
In their 2009 human study Sackmann-Sala and colleagues used 2D-gel electrophoresis and subsequent mass spectrometry to identify proteins from serum-paired samples (pre- and 1 week post-CJC-1295 exposure) from 11 young and healthy men. Two protein spots decreased in intensity: An apolipoprotein A1-isoform and a Transthyretin-isoform. There were also fragments of Albumin among the other changed proteins. The biological meaning of these candidate markers was still unresolved.
The “spot” refers to the area on a gel that corresponds to a measurement obtained from that part of the gel. Changes in an isoform of a protein or in a fragment of a protein are not necessarily reflected in the intact protein from which these “spots” were obtained. One of the “spots” containing fragments of immunoglobulins and albumin correlated with IGF-I levels. It is not known whether it was the fragments of immunoglobulins or the albumin fragments or something else in that “spot” that correlated with IGF-I.
Three clocks, not one
Early work with rats found that CJC-1295 was detectable beyond 72 hours. Jetté’s Western blot showed an immunoreactive species within the albumin band after 15 minutes and beyond 24 hours. These data support conjugation of CJC-1295 to albumin but are quite different from the half-life information provided by Teichman for human studies. “Detected beyond” gives you an observation window but does not automatically translate into a half-life for a particular compound.
A stated duration needs to say what was followed and how. As an example, an albumin-band on a Western blot would give a different kind of evidence to that of the concentration of the compound itself followed over time or the time course of IGF-I levels.
| Reported observation | What it described | What it did not establish |
|---|---|---|
| CJC-1295 detected beyond 72 hours in rats | Persistence of a measurable plasma signal | A human half-life |
| Estimated half-life of 5.8 to 8.1 days in adults | Pharmacokinetics of the studied long-acting molecule | The half-life of every sample labelled CJC-1295 |
| Raised IGF-I for nine to eleven days | A downstream concentration time course | Direct measurement of intact peptide throughout that period |
| Preserved GH pulses with raised troughs | A sampled secretion pattern | An unchanged baseline or larger pulses |
An earlier article carried a storage table, but the primary abstracts here do not support any container-stability figures, so we left it out. A plasma half-life is distinct from the shelf life of a dry sample, and the fact that a reagent is resistant to an enzyme does not imply that a prepared solution is stable. Such data must be obtained from separate papers on individual materials. These papers are not them.
What was the assay looking for?
This naming problem goes far beyond semantics. Henninge and colleagues used liquid chromatography with high-resolution tandem mass spectrometry in their 2010 study to identify an unknown preparation. A 29-amino-acid peptide with a C-terminal amide was found. The proposed sequence of this peptide was consistent with material then called CJC-1295, but did not establish that it was the original albumin-conjugating construct.
Two different compounds, GHRH(1-29) with an added modified terminal lysine and a 29-amino-acid peptide with a C-terminal amide, were studied by Jetté and Henninge. Because we are uncertain about the correct chemical formula of “CJC-1295” we will not provide a formula for “CJC-1295” in this review.
A strategy to identify GHRHs including CJC-1295 in human plasma using immunoaffinity purification followed by detection with high-resolution tandem mass spectrometry (MS/MS) was developed by Knoop and colleagues. The method was validated for specificity, matrix effects, and sensitivity. A limitation of the study relates to possible species differences in the metabolism and excretion of certain analytes of interest, and thus further studies are warranted to address these differences.
However, individual CJC-1295 molecules can also become part of very large macromolecular protein conjugates with undefined molecular weight. For this reason, screening assays for free (unconjugated) peptide can fail to detect CJC-1295 when it is attached to protein in equine plasma using a top-down peptide screening approach. Timms and colleagues described that problem in 2019.
The assay described by Timms et al. (2019) used antibodies raised against CJC-1295 in an immuno-polymerase chain reaction (I-PCR) format to detect CJC-1295 that was part of a large macromolecular protein conjugate. Endogenous equine GHRH affected the screening threshold. These data would be very different from that generated by the Henninge identification of an unknown preparation and thus the same compound name can be used with different target descriptions.
The absence of a signal in a bioanalytical assay is usually hard to explain without information on what was assayed: the peptide in the free form, a peptide fragment or a CJC-1295-protein conjugate. A positive identification of an unknown does not automatically also prove the purity of the analyte. A mass spectrum consistent with an expected peptide does not, on its own, establish the absence of contamination.
A few boundaries worth keeping
While these papers present many different types of evidence, they should not be read as one long experiment presented in installments. Eleven paired serum samples from a single experiment are clearly different from a single rat blot, and a receptor-cloning experiment presents additional information. The different models and endpoints of evidence presented in these papers provide much more information than a single list of claims presented in neat fashion.
The article about CJC-1295 and ipamorelin goes into the combination of these two compounds in more detail. None of the experiments summarized above for CJC-1295 were done with the other compound. Adding a second name to a later section does not make an experiment with one compound evidence about both compounds together.
The raised trough is notable on its own. That overnight experiment did not test all parts of the feedback system, so one cannot say that all feedback stayed intact.
Frequently asked questions
Is CJC-1295 the same thing as GH?
No, even though the names can look similar. CJC-1295 is the synthetic GHRH analog for which we provide information on this page. GH refers to the natural endogenous hormone that was measured in the studies performed with these compounds.
Does the published half-life apply without DAC?
And no, Teichman does not give a general transferable number here (5.8 to 8.1 days). The estimate came from the studied long-acting form of the peptide, not from every compound subsequently given a similar name. So structure and citation must match.
Did the human study find that GH pulses stopped?
GH pulses did not stop in the Ionescu and Frohman study. Frequency and magnitude were unchanged at the one-week comparison, while trough and mean GH increased. Remember only the preserved pulses and you miss the higher troughs in that same experiment.
References
- Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005. PMID 15817669.
- Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism. 2006. PMID 16352683.
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology & Metabolism. 2006. PMID 17018654.
- Mayo KE. Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone. Molecular Endocrinology. 1992. PMID 1333056.
- Alba M, Fintini D, Sagazio A, et al. […] CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse . American Journal of Physiology, Endocrinology and Metabolism. 2006. PMID 16822960.
Lorem ipsum dolor sit amet...
- Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Hormone & IGF Research. 2009. PMID 19386527.
- Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Testing and Analysis. 2010. PMID 21204297.
- Knoop A, Thomas A, Fichant E, et al. Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS. Analytical and Bioanalytical Chemistry. 2016. PMID 26879649.
- Timms M, Ganio K, Forbes G, Bailey S, Steel R. An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma. Drug Testing and Analysis. 2019. PMID 30489688.
Disclaimer: This content is intended for research purposes only and is not meant to constitute medical advice.
This educational material discusses laboratory research concepts only. Loti Labs products are intended strictly for research and development use and are not for human consumption.